Novo Nordisk’s reply to call for withdrawal of liraglutideBMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e3706 (Published 01 June 2012) Cite this as: BMJ 2012;344:e3706
- Alan Moses, global chief medical officer1
- 1Novo Nordisk, 100 College Road West, Princeton, NJ 08540, USA
Novo Nordisk is committed to patient safety and rejects Public Citizen’s assertion that the benefits of liraglutide (Victoza) are outweighed by its risks.1 Moreover, we believe that the comparison to the glitazone class in the news story is inappropriate because of different mechanisms of action.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial